Cribstone Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cribstone Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,431	Closed	-$10K	–	509
2019 Q3	$10K	Sell	1,431 -240	-14%	-$1.84K	0.01%	421
2019 Q2	$15K	Hold	1,671	–	–	0.01%	394
2019 Q1	$26K	Hold	1,671	–	–	0.01%	329
2018 Q4	$26K	Hold	1,671	–	–	0.01%	339
2018 Q3	$36K	Hold	1,671	–	–	0.02%	322
2018 Q2	$41K	Hold	1,671	–	–	0.02%	302
2018 Q1	$29K	Hold	1,671	–	–	0.01%	326
2017 Q4	$32K	Sell	1,671 -1,370	-45%	-$20.6K	0.02%	372
2017 Q3	$54K	Buy	3,041 +250	+9%	+$5.63K	0.03%	249
2017 Q2	$93K	Sell	2,791 -350	-11%	-$10.8K	0.05%	193
2017 Q1	$101K	Buy	3,141 +100	+3%	+$3.41K	0.06%	196
2016 Q4	$101K	Sell	3,041 -200	-6%	-$7.99K	0.06%	171
2016 Q3	$144K	Buy	3,241 +41	+1%	+$2.14K	0.09%	132
2016 Q2	$161K	Buy	+3,200	New	+$170K	0.1%	125

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Cribstone Capital Management's TEVA Position: Q4 2019 in Review

Cribstone Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 1,431 shares — an estimated $10K sold.

Cribstone Capital Management first reported a position in TEVA in Q2 2016 and held it in 14 quarters. The position peaked at $161K in Q2 2016. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Cribstone Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Cribstone Capital Management sold 1,431 Teva Pharmaceuticals shares in Q4 2019, an estimated $10K.
Cribstone Capital Management first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 14 quarters.
Cribstone Capital Management's Teva Pharmaceuticals position peaked at $161K in Q2 2016.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Cribstone Capital Management's 13F filing for Q4 2019, filed 8 Jan 2020.